Effects of cilostazol on lipid and fatty acid metabolism

Clinical and Experimental Medicine

Volumn 4, Issue 4, 2005, Pages 170-173

  Nakamura, N ^a   Osawa, H ^a   Yamabe, H ^a   Okumura, K ^a   Hamazaki, T ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cilostazol; Docosahexaenoic acid; Polyunsaturated fatty acid; Serum lipid

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C2; CHOLESTEROL; CILOSTAZOL; DOCOSAHEXAENOIC ACID; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PENTOXIFYLLINE; PHOSPHODIESTERASE III INHIBITOR; PLACEBO; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY ACID METABOLISM; HEADACHE; HEART PALPITATION; HUMAN; INFLAMMATION; INTERMITTENT CLAUDICATION; LIPID BLOOD LEVEL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION; WITHDRAWAL SYNDROME;

AGED; ATHEROSCLEROSIS; DOUBLE-BLIND METHOD; FATTY ACIDS; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; LIPID METABOLISM; MALE; PHOSPHODIESTERASE INHIBITORS; TETRAZOLES; TREATMENT OUTCOME;

EID: 17644402787     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-004-0052-1     Document Type: Review

References (31)

1. Kimura Y, Tani T, Kanbe T, Watanabe K (1985) Effects of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35:1144-1149
2. Okuda Y, Kimura Y, Yamashita K (1993) Cilostazol. Cardiovasc Drug Rev 11:451-456
3. Takazakura E, Osawa K, Hamamatsu K (1989) Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients. Jpn Pharmacol Ther 17:311-315
4. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB, Forbes WP (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942-1947
5. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr (1998) Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98:678-686
6. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP (1998) Effect of cilostazol on walking distance in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27:267-274
7. Otsuka America Pharmaceutical Inc. (1998) Cilostazol for use in patients with intermittent claudication. Advisory Committee Meeting Dossier (Cilostazol OPC-13013) June 3
8. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, Forbes WP (1999) A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 159:2041-2050
9. Dawson DL, DeMaioribus CA, Hagino RT, Light JT, Bradley DV Jr, Britt KE, Charles BE (1999) The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 178:141-146
10. Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey E, Forbes WP, Strandness DE Jr (2000) A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109:523-530
11. Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, Forbes WP (2002) Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovasc Surg 36:83-91
12. Nakamura N, Hamazaki T, Johkaji H, Minami S, Yamazaki K, Satoh A, Sawazaki S, Urakaze M, Kobayashi M, Osawa H, Yamabe H, Okumura K (2003) Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. Clin Exp Med 2:180-184
13. Bjornsson OG, Sparks JD, Sparkset CE, Gibbons GF (1994) Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinase. Eur J Clin Invest 24:137-146
14. Motobayashi T, Morita T, Ueki H (1996) Involvement of the rapid increase in cAMP content in the vanadate-stimulates release of lipoproteins lipase activity from rat fat pads. Biol Pharm Bull 19:1412-1416
15. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y (2000) Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 152:299-305
16. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ (1993) Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71
17. Campos E, Nakajima K, Tanaka A, Havel RJ (1992) Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 33:369-380
18. Sakata K, Miho N, Shirotani M, Yoshida H, Tanaka Y, Tanaka A (1998) Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary. Atherosclerosis 136:225-231
19. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW (2004) Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109:1022-1028
20. Kromann N, Green AL (1980) Epidemiological studies in the Upernavik District, Greenland. Acta Med Scand 208:401-406
21. Bang HO, Dyerberg J, Nielsen AB (1971) Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet I:1143-1145
22. Dyerberg J (1986) Linoleate-derived polyunsaturated fatty acids and prevention of atherosclerosis. Nutr Rev 44:125-134
23. Salem N Jr, Kim HY, Yergey JA (1986) Docosahexaenoic acid: membrane function and metabolism. In: Simopoulos AP, Kifer RR, Martin RE (eds) Health effects of polyunsaturated fatty acids in seafoods. Academic Press, Orlando, FL, pp 263-317
24. Yamamoto N, Saito M, Moriuchi A, Nomura M, Okuyama H (1987) Effect of dietary a-linolinate/linoleate balance on brain lipid composition and learning ability of rats. J Lipid Res 28:144-151
25. Neuringer M, Conner WE, Petten CV, Barstad J (1984) Dietary omega-3 fatty acid deficiency and visual loss in infant rhesus monkeys. J Clin Invest 73:272-276
26. von Schacky C, Weber PC (1985) Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 76:2446-2450
27. Guffy MM, Rosenberger JA, Simon I, Burns CP (1982) Effect of cellular fatty acid alteration on hyperthermic sensitivity in cultured L1210 murine leukemia cells. Cancer Res 42:3625-3630
28. McLennan PL, Abeywardena MY, Charnock JS (1988) Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J 116:709-717
29. Nakamura N, Hamazaki T, Yamazaki K, Taki H, Kobayashi M, Yazawa K, Ibuki F (1993) Intravenous infusion of tridocosahexaenoyl-glycerol emulsion into rabbits: effects on leukotriene B4/5 production and fatty acid composition of plasma and leukocytes. J Clin Invest 92:1253-1261
30. Mallikaarjun S, Forbes WP, Bramer SL (1999) Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. Clin Pharmacokinet 37[Suppl 2]:33-40
31. Bramer SL, Forbes WP (1999) Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. Clin Pharmacokinet 37[Suppl 2]:25-32